Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors

期刊论文
出版模式：

开放获取
发表日期：

2024年4月10日

查看全文

Denise S. Hoogenkamp,
Linda J. de Wit–van der Veen,
Daphne M. V. Huizing,
Margot E. T. Tesselaar,
Rachel S. van Leeuwaarde,
Marcel P. M. Stokkel,
Marnix G. E. H. Lam,
Arthur J. A. T. Braat

摘要

Purpose of Review

To provide insights into the role of peptide receptor radionuclide therapy (PRRT) in patients with advanced neuroendocrine tumors (NET) and an overview of possible strategies to combine PRRT with locoregional and systemic anticancer treatments.

Recent Findings

Research on combining PRRT with other treatments encompasses a wide variety or treatments, both local (transarterial radioembolization) and systemic therapies, chemotherapy (i.e., capecitabine and temozolomide), targeted therapies (i.e., olaparib, everolimus, and sunitinib), and immunotherapies (e.g., nivolumab and pembrolizumab). Furthermore, PRRT shows promising first results as a treatment prior to surgery.

Summary

There is great demand to enhance the efficacy of PRRT through combination with other anticancer treatments. While research in this area is currently limited, the field is rapidly evolving with numerous ongoing clinical trials aiming to address this need and explore novel therapeutic combinations.